Nuciferine activates intestinal TAS2R46 to attenuate metabolic disorders and hyperlipidemia via hepatic VLDL regulation.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published Date:

Abstract

BACKGROUND: Dysregulated blood lipid metabolism, a primary driver of hyperlipidemia, is closely associated with excessive very low-density lipoprotein (VLDL) synthesis and secretion. Nuciferine, a bioactive compound isolated from lotus leaves, demonstrates remarkable hypolipidemic efficacy; however, its limited bioavailability challenges existing mechanistic explanations for this pronounced therapeutic effect.

Authors

  • Chen Ding
    Department of Cardiology, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, Jiangsu, China.
  • Jian Ruan
    Faculty of Geomatics, East China Institute of Technology, 330013, Nanchang, PR, China.
  • Jingxian Huang
    School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Ministry of Education, Yantai University, Yantai 264005, PR China.
  • Limin Liu
    Electrical and Electronic Teaching Center, Electronics Information Engineering College, Changchun University, Changchun 130022, China.
  • Yu Li
    Department of Public Health, Shihezi University School of Medicine, 832000, China.
  • Yuan Du
    School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Ministry of Education, Yantai University, Yantai 264005, PR China. Electronic address: duyuan@ytu.edu.cn.
  • Yan Zhao
    Emergency Center, Hubei Clinical Research Center for Emergency and Resuscitaion, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.